Crossject engage Syn
Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-Unis
04 janv. 2024 12h00 HE | CROSSJECT
Communiqué de presse Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-Unis  Crossject élargit ses activités d'accès au marché dans le cadre des...
Crossject engages Sy
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
04 janv. 2024 12h00 HE | CROSSJECT
Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®  Crossject expanding market access activities in preparation for filing for marketing authorization ...
Crossject reports fi
Crossject reports financial results and business highlights for first half of 2023
26 sept. 2023 11h35 HE | CROSSJECT
Press Release Crossject reports financial results and business highlights for first half of 2023   Strong progress in bringing drugs for use in emergency situations towards the market ...
Crossject présente s
Crossject présente ses résultats financiers et faits marquants du premier semestre 2023
26 sept. 2023 11h35 HE | CROSSJECT
Communiqué de presse Crossject présente ses résultats financiers et faits marquants du premier semestre 2023   De solides avancées vers la mise sur le marché de médicaments dédiés aux situations...
FINAL lOGO.png
Injectable Drug Delivery Market is anticipated to reach beyond US$ 101.2 Billion by the end of 2033, Persistence Market Research
22 mars 2023 09h35 HE | Persistence Market Research
New York, March 22, 2023 (GLOBE NEWSWIRE) -- The Injectable Drug Delivery Market was about US$ 41.5 Billion in 2022 to US$ 101.2 Billion by 2033, With at a CAGR of 8.4%. Injectable drug delivery...